BioLM
BioLM (Biolinguic Inc.) is a SaaS and professional services company that provides an API-first biological AI platform serving biotech firms, academics, and synthetic biology companies with 50+ GPU-backed protein, antibody, and DNA models, usage-based pricing, and custom workflow services.
- Company typePrivate
- Founded2022
- HeadquartersOakland, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What BioLM does
BioLM, operated by Biolinguic Inc., is a 2022-founded SaaS and professional services company providing an API-first biological AI platform for protein, antibody, and DNA modeling. The platform serves 50+ AI models — including ESM-2, AlphaFold2, ProGen2, AbLang-2, ESMFold, Boltz-2, ZymCTRL, and Evo — via GPU-backed REST APIs and a no-code BioLM Console with chat agents, a Python SDK with DuckDB-based caching, hosted JupyterLab notebooks, and a custom LLM finetuning pipeline supporting DeepSpeed/PB2/ASHA schedulers and hyperparameter optimization.
The company monetizes through tiered subscriptions (Starter at $0, Premium at $20/month, Professional at $350/month with finetuning, and a custom Enterprise tier offering on-premises deployment, priority support, and bespoke app development), supplemented by usage-based pay-per-second API billing that ranges from $0.000046/second for lightweight MPNN models to $0.004643/second for AlphaFold2. A separate Professional Services line delivers custom AI workflow development, fine-tuning, and wet-lab coordination to biotech clients lacking in-house ML capabilities. Distribution combines product-led self-serve onboarding (with $25 free credit upon sign-up) for individual researchers and SMB biotech teams with direct enterprise sales for services engagements.
Customer reach spans biotech and pharmaceutical companies (primary segment), academic researchers, and synthetic biology companies; named engagements include Caravel Bio (4x catalyst productivity improvement in under 2 months on enzyme temperature optimization) and Rhea's Factory (optimized enzyme sequence generation). The platform reports a user base of 1,000+ industry professionals and academics and has actively expanded its surface in 2025 through a production MCP server for AI-agent integrations (April 2025), a BioLM Community Slack (August 2025), and Kedro and Nextflow workflow integrations (September 2025).
BioLM firmographics
Firmographics- Name
- BioLM
- Legal name
- Biolinguic Inc.
- Website
- https://biolm.ai
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioLM (Biolinguic Inc.) is a SaaS and professional services company that provides an API-first biological AI platform serving biotech firms, academics, and synthetic biology companies with 50+ GPU-backed protein, antibody, and DNA models, usage-based pricing, and custom workflow services.
- Ownership category
- akta.pro rank
BioLM industry classification
Industry- Product category
- Biological AI / Computational Biology Platform
- NAICS
- Software Publishers (513210), Computer Systems Design and Related Services (54151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
Keywords
Where BioLM is headquartered
LocationHeadquarters
- HQ city
- Oakland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioLM business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Operations
Revenue model
- API Platform Subscription: Tiered subscription plans (Starter, Premium, Professional, Enterprise) providing API access to biological AI models with varying levels of API requests, model concurrency, and commercial usage rights.
- Usage-Based API Billing: Pay-per-second pricing for individual model endpoints, with rates ranging from $0.000046/second (MPNN models) to $0.004643/second (AlphaFold2).
- Professional Services: Custom AI workflow development, model fine-tuning, and wet-lab coordination services for clients without in-house ML capabilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free tier for anyone looking to try the platform |
| Subscription | Monthly | For professionals and academics ramping up usage |
| Subscription | Monthly | For finetuning and larger teams needing additional access |
| Subscription | Multi-year contract | Custom pricing for on-premises, priority support, and bespoke solutions |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
BioLM product offering
Product offeringCore offering
BioLM provides a GPU-backed biological AI platform delivered through a SaaS web console and REST API, offering access to 50+ protein, antibody, and DNA models (including ESM-2, AlphaFold2, ProGen2, AbLang-2) for sequence embeddings, structure prediction, molecule generation, and classification. The company bundles the platform with a Python SDK (biolmai) featuring DuckDB-based caching, no-code chat agents, an MCP server, hosted Jupyter notebooks, and tiered subscription/usage-based billing. BioLM also offers professional services for custom AI workflow development, fine-tuning, and end-to-end dry-lab to wet-lab validation for biotech clients.
Product overview
BioLM is a biological AI platform providing a cloud-based SaaS product (the BioLM Console) alongside a library of 50+ API models for protein, antibody, and DNA analysis. The platform is offered as a unified solution combining the BioLM Console (for no-code access via Chat Agents), a Python SDK for programmatic API access (with DuckDB-based caching for pipeline automation), LLM Finetuning capabilities for custom model training, and hosted Jupyter Notebooks. Professional Services and Partnering Services are offered as advisory and custom workflow offerings for biotech companies without in-house ML teams. The platform is backed by a cloud infrastructure of GPU-backed REST APIs with usage-based pricing across Starter, Premium, Professional, and Enterprise plan tiers.
Differentiator
Problem solved
Functional benefit
Products and services
- BioLM Platform / BioLM Console Cloud-based SaaS platform providing GPU-backed APIs for protein, antibody, and DNA AI model predictions, embeddings, and generation. Used by 1,000+ industry professionals and academics for real-time molecule generation and model predictions.
- BioLM API Models Library of 50+ biological AI API models including ESM-2, AlphaFold2, ProGen2, AbLang-2, ABodyBuilder2, ESMFold, and others covering protein structure prediction, antibody engineering, enzyme optimization, DNA analysis, and generative protein design. Available via REST API with pay-per-second pricing.
- AI Chat Agents No-code chat agent interfaces for accessing transformer, diffusion, evolutionary, and bio-LLM models using natural language. Agents include ESMFold, ProGen2, ProteInfer, ESM-1v, and AbLang for protein structure prediction, generation, GO/EC prediction, masked amino acid prediction, and antibody restoration.
- BioLM Python SDK (biolmai) Python client library (biolmai) providing programmatic access to BioLM's API models. Includes a DataPipeline module for orchestrating multi-step prediction workflows, DuckDB-based caching for deduplication and zero-cost re-querying, and integration with Kedro and Nextflow for workflow management.
- Professional Services Custom AI workflow building, fine-tuning, and consulting for biotech companies. Includes lead optimization, candidate selection and in-silico screening, and closing the loop with wet-lab validation for enzyme and antibody projects. Offered for smaller biotech firms needing augmented ML expertise.
- Partnering Services Royalty-free bio-AI expertise for companies without in-house ML. BioLM builds state-of-the-art models for industrial single-cell, protein, and DNA use-cases, including dry-lab to wet-lab experience, and determines the best AI plan-of-action tailored to client needs.
- Hosted JupyterLab Environment Hosted JupyterLab environment (jupyter.biolm.ai) providing interactive tutorials and notebooks for using BioLM's models and SDKs, including guides for ESMFold, ProGen2, ESM-1v deep mutational scanning, and antibody engineering workflows.
Quantifiable outcome
- 10°C improvement in optimal enzyme temperature in first library of <100 variants
- +2 more outcomes
Companies that use BioLM
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
BioLM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
AI capability8 records
Feature6 records
BioLM partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights6 records
BioLM competitors and assessment
Company assessmentBroad incumbents
- Insitro: Insitro combines ML with high-throughput biology for drug discovery — overlapping BioLM's AI-for-biology thesis but with substantially larger capital and an internal therapeutics pipeline.
- Benchling: Benchling is a leading cloud-based lab informatics platform serving biotech R&D teams; while not a model API, it competes for the same biotech IT budget and increasingly embeds AI/ML capabilities for biological data.
- Schrödinger: Schrödinger provides computational chemistry and biology software (including LiveDesign) used by pharma for molecular design, broadly overlapping BioLM's biotech customer base and predictive modeling capabilities.
- Generate Biomedicines: Generate Biomedicines operates a generative biology platform (Chroma) for protein design with internal pipeline assets; it competes with BioLM's generative protein and antibody design offerings while also pursuing internal therapeutics.
- Recursion: Recursion operates a techbio platform using AI and high-throughput wet-lab experimentation, overlapping BioLM's combined dry-/wet-lab value proposition though at much greater scale and capital intensity.
- Valo Health: Valo Health uses AI across the drug discovery continuum with an integrated wet-lab component, broadly comparable to BioLM's end-to-end AI-to-wet-lab approach but focused on internal pipeline development.
Direct peers
- Profluent Bio: Profluent develops frontier protein language models and provides API access for protein generation and engineering, positioning it as a near-direct competitor to BioLM's ProGen2/ESM-2 model catalog and developer-first GTM.
- EvolutionaryScale: EvolutionaryScale builds large genomic/protein language models (ESM, Evo) and exposes them via API — a direct rival in the foundation-model-for-biology space that BioLM also serves.
- Cradle: Cradle offers a bio-AI platform for protein engineering with API/web access to generative and predictive models, directly overlapping BioLM's protein design and lead optimization use cases for biotech customers.
Emerging players
- Absci: Absci offers AI-driven generative antibody design and wet-lab validation; it overlaps BioLM's antibody engineering (AbLang, ABodyBuilder) and wet-lab feedback loop offerings with an emerging platform play.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
BioLM social profiles
Digital presenceBioLM financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioLM leadership team
Management profileNumber of profiles
Profiles4 records
BioLM funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioLM M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioLM
What does BioLM do?
BioLM provides a GPU-backed biological AI platform delivered through a SaaS web console and REST API, offering access to 50+ protein, antibody, and DNA models (including ESM-2, AlphaFold2, ProGen2, AbLang-2) for sequence embeddings, structure prediction, molecule generation, and classification. The company bundles the platform with a Python SDK (biolmai) featuring DuckDB-based caching, no-code chat agents, an MCP server, hosted Jupyter notebooks, and tiered subscription/usage-based billing. BioLM also offers professional services for custom AI workflow development, fine-tuning, and end-to-end dry-lab to wet-lab validation for biotech clients.
Is BioLM a public or private company?
BioLM is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioLM founded?
BioLM was founded in 2022. It employs 1 to 10 people.
Where is BioLM based?
BioLM is headquartered in Oakland, United States, in the North America region.
How does BioLM make money?
Three revenue lines are on record. API Platform Subscription is the primary driver. The others are usage-Based API Billing and professional Services.
Who are BioLM's main competitors?
Broad incumbents on record are Insitro, Benchling, Schrödinger, Generate Biomedicines, Recursion and Valo Health. Direct peers are Profluent Bio, EvolutionaryScale and Cradle. Absci is listed as an emerging player.
Does BioLM have an API?
Yes. BioLM provides a REST API for protein, antibody, and DNA AI model predictions, embeddings, and generation. The API supports HTTP POST requests with token-based authentication and provides real-time model predictions. A Python SDK is offered. Billing is usage-based (pay-per-second). Models are served via GPU-backed infrastructure. Developer documentation is at api.biolm.ai.
What industry is BioLM in?
BioLM's product category is Biological AI / Computational Biology Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 513210 and its SIC code is 7372.